Author

Lucie Gack

Martin Luther University Halle-Wittenberg

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

Andrea SinziD· 1 shared Christian H. IhlingiD· 1 shared Dirk HeckliD· 1 shared Hasan IssaiD· 1 shared Jan‐Henning KlusmanniD· 1 shared K SchuscheliD· 1 shared Katja Menge· 1 shared L. Cifarelli· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Andrea SinzORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Activation of the TP53 pathway is a therapeutic vulnerability in NUP98::KDM5A+ pediatric AML

L. Cifarelli, Hasan Issa, Ludovica Proietti, K Schuschel, Lucie Gack, Katja Menge, Christian H. Ihling, Meike Vogler, Andrea Sinz, Jan‐Henning Klusmann, Dirk Heckl

This study identifies TRIP13 as a developmentally restricted dependency in NUP98::KDM5A+ pediatric AML, showing that its inhibition reactivates TP53 and kills leukemic cells.

bioRxiv · Sep 11, 2025 · PreprintCancer Biology